- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1364-8535
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients ; volume:24 ; number:1 ; day:23 ; month:11 ; year:2020 ; pages:1-10 ; date:12.2020
Critical care ; 24, Heft 1 (23.11.2020), 1-10, 12.2020
- Creator
-
Jonmarker, Sandra
Hollenberg, Jacob
Dahlberg, Martin
Stackelberg, Otto
Litorell, Jacob
Everhov, Åsa H.
Järnbert-Pettersson, Hans
Söderberg, Mårten
Grip, Jonathan
Schandl, Anna
Günther, Mattias
Cronhjort, Maria
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13054-020-03375-7
- URN
-
urn:nbn:de:101:1-2021010318292682081354
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Jonmarker, Sandra
- Hollenberg, Jacob
- Dahlberg, Martin
- Stackelberg, Otto
- Litorell, Jacob
- Everhov, Åsa H.
- Järnbert-Pettersson, Hans
- Söderberg, Mårten
- Grip, Jonathan
- Schandl, Anna
- Günther, Mattias
- Cronhjort, Maria
- SpringerLink (Online service)
Other Objects (12)
Risk factors for and prediction of mortality in critically ill medical–surgical patients receiving heparin thromboprophylaxis
Thromboprophylaxis patterns and determinants in critically ill patients: a multicenter audit
COVID-19: opening a new paradigm in thromboprophylaxis for critically ill patients?
Antifungal Dosing in Critically Ill Patients on Extracorporeal Membrane Oxygenation
Mortality data from omission of early thromboprophylaxis in critically ill patients highlights the importance of an individualised diagnosis-related approach
Optimizing micafungin dosing in critically ill patients: what about extracorporeal therapies?
High level of venous thromboembolism in critically ill trauma patients despite early and well-driven thromboprophylaxis protocol
Antibiotic dosing recommendations in critically ill patients receiving new innovative kidney replacement therapy
We need to optimize piperacillin-tazobactam dosing in critically ill patients—but how?
Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19
Intensive insulin therapy and mortality in critically ill patients
Visfatin Serum Levels Predict Mortality in Critically Ill Patients
Risk factors for and prediction of mortality in critically ill medical–surgical patients receiving heparin thromboprophylaxis
Thromboprophylaxis patterns and determinants in critically ill patients: a multicenter audit
COVID-19: opening a new paradigm in thromboprophylaxis for critically ill patients?
Antifungal Dosing in Critically Ill Patients on Extracorporeal Membrane Oxygenation
Mortality data from omission of early thromboprophylaxis in critically ill patients highlights the importance of an individualised diagnosis-related approach
Optimizing micafungin dosing in critically ill patients: what about extracorporeal therapies?
High level of venous thromboembolism in critically ill trauma patients despite early and well-driven thromboprophylaxis protocol
Antibiotic dosing recommendations in critically ill patients receiving new innovative kidney replacement therapy
We need to optimize piperacillin-tazobactam dosing in critically ill patients—but how?
Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19
Intensive insulin therapy and mortality in critically ill patients
Visfatin Serum Levels Predict Mortality in Critically Ill Patients
Risk factors for and prediction of mortality in critically ill medical–surgical patients receiving heparin thromboprophylaxis
Thromboprophylaxis patterns and determinants in critically ill patients: a multicenter audit
COVID-19: opening a new paradigm in thromboprophylaxis for critically ill patients?
Antifungal Dosing in Critically Ill Patients on Extracorporeal Membrane Oxygenation
Mortality data from omission of early thromboprophylaxis in critically ill patients highlights the importance of an individualised diagnosis-related approach
Optimizing micafungin dosing in critically ill patients: what about extracorporeal therapies?
High level of venous thromboembolism in critically ill trauma patients despite early and well-driven thromboprophylaxis protocol
Antibiotic dosing recommendations in critically ill patients receiving new innovative kidney replacement therapy
We need to optimize piperacillin-tazobactam dosing in critically ill patients—but how?
Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19
Intensive insulin therapy and mortality in critically ill patients